Tirzepatide is a dual GLP-1 and GIP receptor agonist supplied
as a 60 mg lyophilized vial for advanced metabolic and incretin pathway research.
Commonly studied for glucose regulation, appetite signaling,
and systemic energy balance models.
For Research Use Only.
Dual incretin receptor research peptide studied for metabolic regulation,
glucose signaling, and energy balance pathway analysis.
Tirzepatide is a synthetic peptide that functions as a
dual agonist of GLP-1 (Glucagon-Like Peptide-1) and
GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors.
By activating two incretin pathways simultaneously, Tirzepatide is widely studied
in laboratory environments for its role in metabolic signaling, insulin response models,
and appetite-regulating mechanisms.
Investigated for its combined GLP-1 and GIP receptor engagement,
allowing comprehensive metabolic pathway analysis.
Studied in controlled laboratory settings to evaluate insulin secretion,
glycemic control mechanisms, and pancreatic response models.
Explored for its influence on hunger signaling and caloric intake modulation
in metabolic research frameworks.
Used in studies analyzing fat metabolism, nutrient partitioning,
and systemic energy balance.
| Compound | Tirzepatide |
|---|---|
| Amount | 60 mg per vial |
| Form | Lyophilized powder |
FOR RESEARCH USE ONLY. This product is not intended for human consumption,
medical use, diagnosis, treatment, or prevention of any disease.
Sold strictly for laboratory and scientific research purposes.
By purchasing, the buyer agrees to use this product in compliance with all applicable laws and regulations.